2 April 2020 - - US-based life science company Agilent Technologies Inc. (NYSE: A) has introduced the Agilent K6460S Clinical Edition TQ LC/MS system, designed to improve in vitro diagnostic workflows in clinical labs, the company said.

Agilent's next-generation clinical edition triple quadrupole LC/MS system, the K6460S, is listed as a Class I medical device with the US Food and Drug Administration.

The system includes a preconfigured liquid chromatograph and mass spectrometer, as well as the clinical edition of Agilent MassHunter software, which provides an easy-to-use and intuitive submission-to-reporting workflow.

When performing diagnostic assays, the K6460S provides the specificity and selectivity that clinical labs require, delivering robust results with more accuracy, and increasing the reliability of target compound detection in complex matrices.

It was also announced in January 2020 that the Agilent LC-MS/MS had been approved by China's national drug administration for use in the China domestic clinical diagnosis market.

Agilent is in providing IVD medical devices to improve the quality of health care globally and has driven investment in this key area to develop and launch robust, reliable LC-MS/MS IVD systems.

These instruments improve and simplify the analysis of samples and address specific workflows to expedite the efficacy of clinical diagnostics.

Agilent Technologies Inc. (NYSE: A) is in the life sciences, diagnostics, and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions.

The company generated revenue of USD 5.16bn in fiscal 2019 and employs 16,300 people worldwide.